Third Rock unveils liquid biopsy biotech, leading $110M bet it can Thrive in early cancer detection
Cancer is the second leading cause of death globally — the earlier it is detected, the better shot patients have of bouncing back. Researchers have long pursued a minimally-invasive, effective test to expose early markers of the often deadly disease, and weeks ago Grail blueprinted its strategy for its blood test for early cancer detection. On Thursday, Third Rock Ventures unveiled its shot at that lofty goal, with the launch of a liquid biopsy company that has raised a meaty $110 million in its first round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.